Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome.
about
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndromeCoasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndromeSevere OHSS: patients should be allowed to weigh the morbidity of OHSS against the benefits of parenthood.Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management."Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.Serum FSH Levels in Coasting Programmes on the hCG Day and Their Clinical Outcomes in IVF ± ICSI CyclesPrediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program.Application of GnRH antagonist in combination with clomiphene citrate and hMG for patients with exaggerated ovarian response in previous IVF/ICSI cycles.Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome.Is Coasting Valuable in All Patients with Any Cause of Infertility?British Fertility Society Policy and Practice Committee: prevention of ovarian hyperstimulation syndrome.Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: a multicentre study.Prevention of severe ovarian hyperstimulation syndrome (OHSS) in IVF patients by steroidal ovarian suppression--a prospective randomized study.Effects of coasting on the outcome of intracytoplasmic sperm injection-embryo transfer cycles.Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation raGanirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome.
P2860
Q24234075-EFCD35A4-2728-40D4-BA5D-17F9F321C04EQ24236480-51F79AA5-90EA-4533-9085-EA0769144D48Q33723984-3F59AE2F-F761-49A4-81C8-97061E91FEA3Q33844520-7F9CFE61-A033-493B-ACCB-DD4021B3C885Q34758107-8B84D8B5-6374-4F86-9DC0-254E193AD9F1Q35810513-0A199077-8160-4115-8EA3-6349892443A3Q36133371-CD819845-32EE-4DC3-96D6-A287B89F882FQ36268373-3AFF5EE0-768C-4C73-AFDF-E6CB155DE04FQ36847973-68B584A6-DCD8-4DC9-9D6F-E50E4E388CB7Q37399331-B95E4816-7984-4FE1-AB47-04AD38AC21D6Q38266109-799F61B1-8B87-459C-B0D9-EE3F3DED937CQ38768708-5C9C2924-630F-48A6-9064-EA0002A260D2Q43669168-79FD1C5E-B150-4540-8F72-296AC09B50CBQ44576514-074A23FC-3FCC-44C6-9368-9FCDA8B24F4BQ44998944-16BE12B4-8278-4466-B60F-A66F11CE602AQ48679851-D3639106-F136-4819-9C4E-CC60ACCA4702Q50645058-7DB7FF5C-2153-4156-A9E6-D33C7190E525
P2860
Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Withholding gonadotropin admin ...... ian hyperstimulation syndrome.
@en
Withholding gonadotropin admin ...... ian hyperstimulation syndrome.
@nl
type
label
Withholding gonadotropin admin ...... ian hyperstimulation syndrome.
@en
Withholding gonadotropin admin ...... ian hyperstimulation syndrome.
@nl
prefLabel
Withholding gonadotropin admin ...... ian hyperstimulation syndrome.
@en
Withholding gonadotropin admin ...... ian hyperstimulation syndrome.
@nl
P2093
P1476
Withholding gonadotropin admin ...... rian hyperstimulation syndrome
@en
P2093
P304
P356
10.1016/S0015-0282(97)81373-8
P407
P50
P577
1997-04-01T00:00:00Z